NCT07877831Active, not recruiting

Vericiguat Use and Incident Atrial Fibrillation in Chronic Heart Failure

Association Between Vericiguat Treatment and Incident Atrial Fibrillation in Patients With Chronic Heart Failure: An Ambispective Cohort Study

Source: ClinicalTrials.gov · Last updated 16 Oct 2026

Brief summary (registry, in English)

This ambispective observational cohort study aims to evaluate the association between vericiguat treatment and incident atrial fibrillation in patients with chronic heart failure. Adult patients treated at Beijing Tsinghua Changgung Hospital between November 2023 and December 2026 will be included, with data collected retrospectively before January 2025 and prospectively thereafter. Patients will be classified according to vericiguat use during routine clinical care. The non-vericiguat group will include patients receiving contemporary guideline-directed medical therapy for chronic heart failure without vericiguat. Treatment decisions will be made by treating physicians rather than assigned by the study investigators. The primary outcome is incident atrial fibrillation during follow-up, including atrial fibrillation, atrial flutter, and subclinical atrial fibrillation. Secondary outcomes include all-cause death and major adverse cardiovascular events.

Status (registry): Active, not recruiting
Study type: Observational
Enrollment: 918 (estimated)
First submitted: 11 Oct 2026
Start date: 1 Nov 2023
Primary completion date: 31 Dec 2026
Lead sponsor: Beijing Tsinghua Chang Gung Hospital
Diseases: Heart failure, Atrial fibrillation
NCT number: NCT07877831

What you commit to

Study type: Observational
Planned participants: 918
From 1 Nov 2023 to the primary completion date, 31 Dec 2026
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Previous history of atrial fibrillation, or atrial fibrillation diagnosed by electrocardiography or Holter monitoring.

Other illness

Acute heart failure or acute worsening of chronic heart failure.
Acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention within 1 month.
Amyloidosis, granulomatous disease, hypertrophic cardiomyopathy, myocarditis, or stress cardiomyopathy.
Untreated moderate-to-severe mitral stenosis or mechanical prosthetic heart valve.
Major congenital heart disease, or simple congenital heart disease with residual hemodynamic lesions.
Severe hepatic impairment, defined as Child-Pugh class C.
Severe pulmonary disease requiring long-term oxygen therapy.
End-stage disease other than heart failure, such as malignant tumor or other disease with life expectancy \<1 year.

Lab values

End-stage renal disease, defined as eGFR ≤15 mL/min/1.73 m2, or chronic dialysis.

Other

Uncontrolled hyperthyroidism.
Pregnancy, breastfeeding, or planned pregnancy.

Who the study is looking for

Age 18 years or older.
Diagnosis of chronic heart failure according to the 2024 Chinese guideline for the diagnosis and treatment of heart failure.
Heart failure with mildly reduced ejection fraction, reduced ejection fraction, or improved ejection fraction.
History, symptoms, or signs of heart failure.
NT-proBNP ≥125 ng/L or BNP ≥35 ng/L.
Left ventricular ejection fraction \<50% on echocardiography.
New York Heart Association functional class II to III.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
No. 168 Litang Road, Changping District, Beijing, China Coordinator of this site? Confirm its status	Beijing	China	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.